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Abstract—The hemostatic and immunostimulating activity and cytotoxicity were determined for a number of
chitosans differing in molecular weight (from 3 to 510 kDa) and degree of acetylation (from 1 to 25 mol%)
that were used as adjuvants in inactivated poliomyelitic, influenza, and live influenza vaccines. It has been
shown that the hemostatic activity of chitosan increased sharply with an increase in its molecular weight. In
oligochitosan with a molecular weight of <16 kDa, it was smaller by a factor of 15–100 than in chitosan with
a molecular weight of 20–510 kDa. The level of increase in the immunogenicity of vaccines containing oli-
gochitosan as adjuvants was not lower than that for the vaccine including high-molecular chitosan. However,
the immunostimulatory activity of oligochitosan depended on the degree of acetylation, reaching a maximum
value at 6 mol%. It was shown that all oligochitosans and chitosans with a molecular mass below ~50 kDa
showed almost no cytotoxicity at a concentration of ≤2.5 mg/mL, which enable their use as adjuvants for
inactivated and live vaccines at the optimal ratio of molecular weight to the degree of acetylation.
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INTRODUCTION
Vaccination is one of the most effective means of
preventing infections. However, the effectiveness of a
number of vaccines is still not high enough, especially
for the elderly. Thus, the problem of creating highly
effective live and inactivated vaccines with increased
immunogenicity remains relevant. Live vaccines, in
contrast to inactivated ones, induce not only serum
IgG antibodies but also secretory IgA antibodies; they
are good stimulants of cellular immunity, have a long
duration of protective action, and protect against drift
variants. However, such vaccines have reduced pro-
phylactic activity for some population groups, in par-
ticular, for the elderly, which is explained by their
strong immunosuppressive effect. One possible means
to increase the effectiveness of vaccines is the use of
adjuvants (AD) [1].
Over the past decade, vaccinologists have started
using the product of chitin deacetylation: chitosan, a
polycationic, low-toxicity, biodegradable, and bio-
compatible polysaccharide consisting of glucosamine
and N-acetylglucosamine units [2]. Chitosan can vary
significantly in such characteristics as molecular
weight (MW), polydispersity, the degree of deacetyla-
tion (DD), and the distribution of residual acetyl
groups over the polymer chain, which determines its
physicochemical and biological properties [3, 4]. Chi-
tosan is not toxic for homoiothermal animals and
plants; it has fungicidal and bactericidal properties. In
the European Union, the use of chitosan hydrochlo-
ride in the medical, food, and cosmetic industries is
permitted.
For the first time in global health practice, studies
have been undertaken to increase the immunogenicity
of live influenza, cold-adapted (CA) vaccine with high-
molecular weight chitosan with an MW of more than
100 kDa as an AD for mucosal and parenteral adminis-
tration [5–8]. It should be noted that, in practical use,
chitosan is divided by MW into high-molecular weight
(>500 kDa), medium weight (>100–500 kDa), low-
molecular weight (>16–100 kDa), and oligochitosan,
which is a product of deep depolymerization of chitosan
with MW of 2–16 kDa [9, 10].
Chitosan with optimal properties is required for use
in vaccine compositions in order to provide better sol-
ubility in physiological environments and low hemag-
glutination capacity, as well as high titers for the
immunogenicity of vaccine preparations.
